Wave Life Sciences (WVE) Stock Overview
A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
WVE Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Wave Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.48 |
| 52 Week High | US$21.73 |
| 52 Week Low | US$5.28 |
| Beta | -1.72 |
| 1 Month Change | 134.32% |
| 3 Month Change | 162.46% |
| 1 Year Change | 30.35% |
| 3 Year Change | 168.10% |
| 5 Year Change | 119.32% |
| Change since IPO | 9.25% |
Recent News & Updates
Subdued Growth No Barrier To Wave Life Sciences Ltd. (NASDAQ:WVE) With Shares Advancing 128%
Dec 16
Wave Life Sciences: Being Realistic, There Is Still So Much To Prove
Dec 05Recent updates
Subdued Growth No Barrier To Wave Life Sciences Ltd. (NASDAQ:WVE) With Shares Advancing 128%
Dec 16Wave Life Sciences: Being Realistic, There Is Still So Much To Prove
Dec 05Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Nov 01Wave Life Sciences Ltd. (NASDAQ:WVE) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Sep 14Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Trimmed Their Revenue Forecasts By 13%
Aug 04Wave Life Sciences Ltd.'s (NASDAQ:WVE) 26% Share Price Surge Not Quite Adding Up
Jul 31We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
Jul 07Risks Still Elevated At These Prices As Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Dive 26%
Jun 01Wave Life Sciences Ltd.'s (NASDAQ:WVE) 41% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Apr 04Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Mar 27
WVE-007 And WVE-006 Will Offer New Treatment Options For Obesity And AATD
Advancing innovative treatments like WVE-007 and WVE-006 could drive revenue growth by addressing current therapy limitations and capturing market share in obesity and AATD.Wave Life Sciences Is A Buy On Pipeline Prospects
Jan 08US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results
Nov 15Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking
Nov 09Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Oct 16There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Sep 25Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Sep 24Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Sep 08We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
Aug 05Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
Jun 25We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Shareholder Returns
| WVE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.0% | 1.4% | 2.6% |
| 1Y | 30.4% | 24.2% | 14.2% |
Return vs Industry: WVE exceeded the US Pharmaceuticals industry which returned 24.8% over the past year.
Return vs Market: WVE exceeded the US Market which returned 14.8% over the past year.
Price Volatility
| WVE volatility | |
|---|---|
| WVE Average Weekly Movement | 43.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: WVE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: WVE's weekly volatility has increased from 23% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 288 | Paul B. Bolno | wavelifesciences.com |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD).
Wave Life Sciences Ltd. Fundamentals Summary
| WVE fundamental statistics | |
|---|---|
| Market cap | US$3.20b |
| Earnings (TTM) | -US$121.95m |
| Revenue (TTM) | US$109.23m |
Is WVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WVE income statement (TTM) | |
|---|---|
| Revenue | US$109.23m |
| Cost of Revenue | US$174.61m |
| Gross Profit | -US$65.38m |
| Other Expenses | US$56.57m |
| Earnings | -US$121.95m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | -59.86% |
| Net Profit Margin | -111.64% |
| Debt/Equity Ratio | 0% |
How did WVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 08:56 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wave Life Sciences Ltd. is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Whitney Ijem | Canaccord Genuity |
| Steven Seedhouse | Cantor Fitzgerald & Co. |